Arrowhead Pharmaceuticals (ARWR) Competitors $22.34 +0.55 (+2.52%) Closing price 04:00 PM EasternExtended Trading$22.28 -0.05 (-0.25%) As of 05:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ARWR vs. QGEN, MRNA, VRNA, BBIO, ELAN, ROIV, GRFS, RVMD, RYTM, and LEGNShould you be buying Arrowhead Pharmaceuticals stock or one of its competitors? The main competitors of Arrowhead Pharmaceuticals include Qiagen (QGEN), Moderna (MRNA), Verona Pharma PLC American Depositary Share (VRNA), BridgeBio Pharma (BBIO), Elanco Animal Health (ELAN), Roivant Sciences (ROIV), Grifols (GRFS), Revolution Medicines (RVMD), Rhythm Pharmaceuticals (RYTM), and Legend Biotech (LEGN). These companies are all part of the "pharmaceutical products" industry. Arrowhead Pharmaceuticals vs. Its Competitors Qiagen Moderna Verona Pharma PLC American Depositary Share BridgeBio Pharma Elanco Animal Health Roivant Sciences Grifols Revolution Medicines Rhythm Pharmaceuticals Legend Biotech Arrowhead Pharmaceuticals (NASDAQ:ARWR) and Qiagen (NYSE:QGEN) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, earnings, dividends, institutional ownership, profitability, analyst recommendations, risk and media sentiment. Do institutionals & insiders believe in ARWR or QGEN? 62.6% of Arrowhead Pharmaceuticals shares are owned by institutional investors. Comparatively, 70.0% of Qiagen shares are owned by institutional investors. 4.3% of Arrowhead Pharmaceuticals shares are owned by insiders. Comparatively, 9.0% of Qiagen shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Which has higher valuation and earnings, ARWR or QGEN? Qiagen has higher revenue and earnings than Arrowhead Pharmaceuticals. Arrowhead Pharmaceuticals is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioArrowhead Pharmaceuticals$3.55M870.06-$599.49M-$1.28-17.45Qiagen$1.98B5.18$83.59M$1.6927.26 Does the media prefer ARWR or QGEN? In the previous week, Qiagen had 3 more articles in the media than Arrowhead Pharmaceuticals. MarketBeat recorded 14 mentions for Qiagen and 11 mentions for Arrowhead Pharmaceuticals. Qiagen's average media sentiment score of 1.33 beat Arrowhead Pharmaceuticals' score of 1.24 indicating that Qiagen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arrowhead Pharmaceuticals 7 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Qiagen 8 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility & risk, ARWR or QGEN? Arrowhead Pharmaceuticals has a beta of 0.94, indicating that its stock price is 6% less volatile than the S&P 500. Comparatively, Qiagen has a beta of 0.64, indicating that its stock price is 36% less volatile than the S&P 500. Is ARWR or QGEN more profitable? Qiagen has a net margin of 18.30% compared to Arrowhead Pharmaceuticals' net margin of 0.00%. Qiagen's return on equity of 14.77% beat Arrowhead Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Arrowhead PharmaceuticalsN/A -40.91% -11.62% Qiagen 18.30%14.77%8.87% Do analysts prefer ARWR or QGEN? Arrowhead Pharmaceuticals currently has a consensus price target of $43.14, indicating a potential upside of 93.12%. Qiagen has a consensus price target of $49.69, indicating a potential upside of 7.84%. Given Arrowhead Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts plainly believe Arrowhead Pharmaceuticals is more favorable than Qiagen.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Arrowhead Pharmaceuticals 0 Sell rating(s) 2 Hold rating(s) 5 Buy rating(s) 2 Strong Buy rating(s) 3.00Qiagen 0 Sell rating(s) 8 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.27 SummaryQiagen beats Arrowhead Pharmaceuticals on 11 of the 17 factors compared between the two stocks. Get Arrowhead Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ARWR and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ARWR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ARWR vs. The Competition Export to ExcelMetricArrowhead PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.09B$3.06B$5.76B$9.84BDividend YieldN/A2.26%3.95%4.02%P/E Ratio-17.4521.2231.3126.60Price / Sales870.06390.30461.30121.37Price / CashN/A44.4437.7659.36Price / Book5.948.0710.026.67Net Income-$599.49M-$54.08M$3.27B$265.59M7 Day Performance7.66%2.26%3.17%3.42%1 Month Performance37.90%3.42%4.34%1.09%1 Year Performance-6.64%18.61%44.11%23.85% Arrowhead Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ARWRArrowhead Pharmaceuticals3.7376 of 5 stars$22.34+2.5%$43.14+93.1%-9.0%$3.09B$3.55M-17.45400Positive NewsQGENQiagen4.0055 of 5 stars$48.92-1.6%$49.69+1.6%+7.3%$10.87B$1.98B28.905,765MRNAModerna4.4891 of 5 stars$25.35-6.5%$42.88+69.2%-68.2%$9.86B$3.24B-3.375,800VRNAVerona Pharma PLC American Depositary Share2.4848 of 5 stars$105.62+0.1%$109.00+3.2%+289.3%$9.14B$42.28M-106.6930Positive NewsBBIOBridgeBio Pharma4.2208 of 5 stars$47.29-3.6%$61.35+29.7%+98.5%$9.04B$221.90M-11.56400ELANElanco Animal Health2.8656 of 5 stars$17.80-0.6%$17.33-2.6%+21.6%$8.84B$4.44B20.709,000ROIVRoivant Sciences3.1844 of 5 stars$11.64-2.3%$16.50+41.8%+1.2%$7.95B$29.05M-16.63860GRFSGrifols3.588 of 5 stars$9.82-3.3%$10.30+4.9%+11.9%$6.75B$7.45B8.3923,822Positive NewsRVMDRevolution Medicines4.318 of 5 stars$35.67-3.6%$69.92+96.0%-12.7%$6.67B$11.58M-7.93250News CoveragePositive NewsRYTMRhythm Pharmaceuticals3.5242 of 5 stars$99.20-3.9%$101.57+2.4%+115.7%$6.59B$156.29M-32.96140Positive NewsInsider TradeLEGNLegend Biotech3.8863 of 5 stars$34.60-2.7%$73.00+111.0%-39.1%$6.36B$627.24M-39.322,609News CoveragePositive NewsAnalyst Forecast Related Companies and Tools Related Companies Qiagen Alternatives Moderna Alternatives Verona Pharma PLC American Depositary Share Alternatives BridgeBio Pharma Alternatives Elanco Animal Health Alternatives Roivant Sciences Alternatives Grifols Alternatives Revolution Medicines Alternatives Rhythm Pharmaceuticals Alternatives Legend Biotech Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ARWR) was last updated on 8/28/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredWhat Are Some Strategies to Help Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arrowhead Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arrowhead Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access